Rhabdomyosarcoma - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 126 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Rhabdomyosarcoma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Rhabdomyosarcoma - Pipeline Review, H1 2016', provides an overview of the Rhabdomyosarcoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma
- The report reviews pipeline therapeutics for Rhabdomyosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Rhabdomyosarcoma therapeutics and enlists all their major and minor projects
- The report assesses Rhabdomyosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Rhabdomyosarcoma

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Rhabdomyosarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rhabdomyosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Rhabdomyosarcoma Overview 8
Therapeutics Development 9
Pipeline Products for Rhabdomyosarcoma - Overview 9
Pipeline Products for Rhabdomyosarcoma - Comparative Analysis 10
Rhabdomyosarcoma - Therapeutics under Development by Companies 11
Rhabdomyosarcoma - Therapeutics under Investigation by Universities/Institutes 12
Rhabdomyosarcoma - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Rhabdomyosarcoma - Products under Development by Companies 15
Rhabdomyosarcoma - Products under Investigation by Universities/Institutes 16
Rhabdomyosarcoma - Companies Involved in Therapeutics Development 17
Bellicum Pharmaceuticals, Inc. 17
Boehringer Ingelheim GmbH 18
Celgene Corporation 19
EpiZyme, Inc. 20
F. Hoffmann-La Roche Ltd. 21
Merrimack Pharmaceuticals, Inc. 22
Morphotek, Inc. 23
Novartis AG 24
Noxxon Pharma AG 25
Shionogi & Co., Ltd. 26
Rhabdomyosarcoma - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
afatinib dimaleate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
bevacizumab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Cellular Immunotherapy for Oncology - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
celyvir - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
everolimus - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
irinotecan hydrochloride - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
NOXS-93 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
ontuxizumab - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
paclitaxel albumin bound - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
pazopanib hydrochloride - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
S-588410 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
tazemetostat - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Rhabdomyosarcoma - Recent Pipeline Updates 82
Rhabdomyosarcoma - Dormant Projects 123
Rhabdomyosarcoma - Discontinued Products 124
Appendix 125
Methodology 125
Coverage 125
Secondary Research 125
Primary Research 125
Expert Panel Validation 125
Contact Us 125
Disclaimer 126

List of Tables

Number of Products under Development for Rhabdomyosarcoma, H1 2016 9
Number of Products under Development for Rhabdomyosarcoma - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Rhabdomyosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 17
Rhabdomyosarcoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 18
Rhabdomyosarcoma - Pipeline by Celgene Corporation, H1 2016 19
Rhabdomyosarcoma - Pipeline by EpiZyme, Inc., H1 2016 20
Rhabdomyosarcoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 21
Rhabdomyosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 22
Rhabdomyosarcoma - Pipeline by Morphotek, Inc., H1 2016 23
Rhabdomyosarcoma - Pipeline by Novartis AG, H1 2016 24
Rhabdomyosarcoma - Pipeline by Noxxon Pharma AG, H1 2016 25
Rhabdomyosarcoma - Pipeline by Shionogi & Co., Ltd., H1 2016 26
Assessment by Monotherapy Products, H1 2016 27
Number of Products by Stage and Target, H1 2016 29
Number of Products by Stage and Mechanism of Action, H1 2016 31
Number of Products by Stage and Route of Administration, H1 2016 33
Number of Products by Stage and Molecule Type, H1 2016 35
Rhabdomyosarcoma Therapeutics - Recent Pipeline Updates, H1 2016 82
Rhabdomyosarcoma - Dormant Projects, H1 2016 123
Rhabdomyosarcoma - Discontinued Products, H1 2016 124